{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:08:09Z","timestamp":1760645289151},"reference-count":17,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":2289,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p>NXY\u2010059 is a free radical\u2014trapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. Acute ischemic stroke patients receiving NXY\u2010059 may also be exposed to diuretics for treatment of heart failure or hypertension. NXY\u2010059 and furosemide are partly eliminated by active tubular secretion via an organic anion transporter. This double\u2010blind, randomized, crossover, placebo\u2010controlled study investigated whether an infusion of NXY\u2010059 (15 mg\/mL) during 12 hours affects the diuretic and saluretic effects of a 30\u2010mg intravenous bolus dose of furosemide (10 mg\/mL) administered after 6 hours' infusion, in 13 male and 11 female healthy subjects. The net increase in urine volume and sodium excretion in the interval of 6 to 12 hours was 4.15 L and 178 mmol\/L, respectively, during NXY\u2010059 treatment (<jats:italic>P<\/jats:italic> = .93) and 4.34 L and 190 mmol\/L, respectively, during placebo treatment (<jats:italic>P<\/jats:italic> = .54). NXY\u2010059 reduced the renal clearance of furosemide by 19% (<jats:italic>P<\/jats:italic> = .019), and furosemide reduced the renal clearance of NXY\u2010059 by 8% (<jats:italic>P<\/jats:italic> = .005). NXY\u2010059 was well tolerated.<\/jats:p>","DOI":"10.1177\/0091270006293372","type":"journal-article","created":{"date-parts":[[2006,11,13]],"date-time":"2006-11-13T19:39:46Z","timestamp":1163446786000},"page":"1417-1425","source":"Crossref","is-referenced-by-count":2,"title":["NXY\u2010059 Does Not Significantly Interact With Furosemide in Healthy Volunteers"],"prefix":"10.1002","volume":"46","author":[{"given":"Stig","family":"Strid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dag","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Borg\u00e5","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Wemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Grahn\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","DOI":"10.30875\/b469a751-en","volume-title":"The World Health Report 2004","author":"World Health Organization.","year":"2004"},{"key":"e_1_2_5_3_2","volume-title":"Heart Disease and Stroke Statistics: 2006 Update","author":"American Heart Association.","year":"2006"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-003-0001-4"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-199907000-00008"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704449"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.32.1.190"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000087790.79851.A8"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00245.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052980"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jscd.2002.123973"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0478-x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.12.260"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00592.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1973.225.1.119"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X121075"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270006293372","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270006293372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:40:38Z","timestamp":1697114438000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270006293372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1177\/0091270006293372"],"URL":"https:\/\/doi.org\/10.1177\/0091270006293372","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}